Starpharma Holdings Limited


 Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.

The Company's lead pharmaceutical development product is VivaGel(R) (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes. 

View in Other Languages


OTC Markets Launches New OTCQX(R) Indices

🕔1/7/2015 9:14:24 AM 7840

OTC Markets Group recently launched the OTCQX Composite Index (.OTCQX), OTCQX International Index (.OTCQXINT) and OTCQX U.S. Index (.OTCQXUS), to provide investors with a benchmark of the established, global and growth companies traded on the OTCQX marketplace.

Read Full Article

Asian Activities Report for October 10, 2011: Carabella Resources (ASX:CLR) Appoints New Managing Director to Strengthen Expertise in the Coal Industry

🕔10/10/2011 12:00:44 PM 13750

Asian Activities Report for October 10, 2011 includes: Carabella Resources Limited (ASX:CLR) announced the appointment of experienced coal industry executive Anthony Quin as Managing Director; Tasman Resources Limited (ASX:TAS) has signed a conditional agreement with Rio Tinto Limited (ASX:RIO) for the funding of an accelerated exploration program on Tasman's Vulcan prospect; Acer Energy Limited (ASX:ACN) has executed a conditional Sale and Purchase Agreement with Sundance Energy Australia Limited (ASX:SEA) to acquire all of Sundance's 23.33% working interest in Petroleum Exploration Licence 100; Starpharma Holdings Limited (ASX:SPL) has received agreement from the US Food and Drug Administration regarding the Phase 3 clinical trial program for the Company's VivaGel (R) bacterial vaginosis treatment.

Read Full Article

Starpharma Holdings Limited's (ASX:SPL) Deal With Elanco Triggers a Share Purchase Plan Extension

🕔5/11/2009 11:44:49 AM 7817

The Board of Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) has decided to further extend the closing date of the share purchase plan (SPP) due to the Elanco Agreement announcement made today.

Read Full Article

Starpharma Holdings Limited (ASX:SPL) and Elanco Sign A Collaborative Research, License And Commercialisation Agreement

🕔5/11/2009 10:32:19 AM 6236

Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) today announced the signing of a collaborative research, license and commercialisation agreement with Elanco, the animal health division of US pharmaceutical company Eli Lilly and Company (NYSE:LLY).

Read Full Article

Starpharma Holdings Limited (ASX:SPL) Raises Additional Capital Up To A$4.6 Million Via Institutional Placement

🕔4/7/2009 9:42:24 AM 7336

Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) today announced a successful capital raising of at least A$4.3 million and up to A$4.6 million, through a private placement to existing and new institutional and sophisticated investors.

Read Full Article

Starpharma Holdings Limited (ASX:SPL) Completes Patient Testing In Retention Of VivaGel Antiviral Activity Study

🕔3/19/2009 12:51:50 PM 7051

Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) today announced the completion of patient testing in a clinical trial of VivaGel(R) that explores the length of time the antiviral activity of VivaGel remains following application.

Read Full Article

Starpharma Holdings Limited (ASX:SPL) Announces Its Financial Results For The 6 Months Ending 31 December 2008

🕔2/19/2009 5:18:11 PM 5669

Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) Net loss after tax was A$1.9 million, with operating cash outflows of A$2.5 million for the half year, 12% less than the same period in the prior year. Cash at 31 December was A$6.1 million. Total revenue and other income was A$5.1 million for the half year with revenue from continuing operations A$1.0 million for the six months, up 6% compared with the same period in the prior year.

Read Full Article

Starpharma Holdings Limited (ASX:SPL) Topical Microbicide Field Receives a Boost with Human Efficacy Result

🕔2/10/2009 1:47:47 PM 4986

Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) welcomes news that PRO2000 gel, a candidate microbicide similar to Starpharma's own VivaGel(R), has demonstrated partial effectiveness in preventing HIV infection in women. The study also found that 99% of women in the trial reported that they would use a topical microbicide gel that was approved for HIV prevention.

Read Full Article

Starpharma Holdings Ltd (ASX:SPL) Quarterly Activities Report to Dec 31, 2008

🕔2/3/2009 1:40:29 PM 4002

Starpharma Holdings Ltd (ASX:SPL)(PINK:SPHRY) Quarterly Activities Report to Dec 31, 2008

Read Full Article

Starpharma Holdings Ltd (ASX:SPL) Dendrimer Reduces Toxicity of Cancer Drug

🕔12/17/2008 1:19:24 PM 5109

Starpharma Holdings Ltd (ASX:SPL)(PINK:SPHRY) today reported an important advance in its dendrimer-based drug-delivery program.

Read Full Article


  • This Page Viewed: (Last 7 Days: 87) (Last 30 Days: 395) (Since Published: 31244) 

Company Data

  • Baker Building
    75 Commercial Road
    Melbourne VIC 3004
  • Telephone
  • +61 3 8532 2700  
  • Fax
  • +61 3 9510 5955  
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Listed
  • 2000/09/28 
  • Homepage

More News Results

  • 2024/04/08: Investor Webinar Notification SPL Medicxi Partnership*
  • 2024/04/08: Starpharma and Medicxi Partnership Petalion Therapeutics*
  • 2024/02/28: Half Yearly Report and Accounts*
  • 2024/02/19: VivaGel BV US FDA Appeal Outcome*
*refer to company website